Istesso: Hambro Perks will not merge with IP Group drug firm Istesso

(marketscreener.com) Hambro Perks Acquisition Co Ltd on Monday responded to press speculation, saying it will not merge with Istesso Ltd, a London-based chronic disease drug developer that is majority owned by IP Group PLC, an Oxford, England-based intellectual property commercialisation company. "HPAC confirms that discussions with Istesso and its major shareholder...https://www.marketscreener.com/quote/stock/IP-GROUP-PLC-38908802/news/Hambro-Perks-will-not-merge-with-IP-Group-drug-firm-Istesso-42844857/?utm_medium=RSS&utm_content=20230130